Condition: Advanced Solid Tumor · Advanced Cancer · Metastatic Cancer · Sponsor: MacroGenics
The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of MGC026 in participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tumors The study has a dose escalation portion and a cohort expansion portion of the study. Participants will receive MGC026 by intravenous (IV) infusion. The dose of MGC026 will be assigned at the time of enrollment. Participants may receive up to 35 treatments if there are no severe side effects and as long as the cancer does not get worse. Participants will be monitored for side effects, and progression of cancer, have blood samples collected for routing laboratory work, and blood samples collected for research purposes.
This description comes directly from the study's public registry record.
Global Trial Manager · 301-251-5172 · info@macrogenics.com
Always discuss trial participation with your own doctor first.
| The Angeles Clinic and Research Institute | Los Angeles, California, United States | Recruiting |
| START Midwest | Grand Rapids, Michigan, United States | Recruiting |
| START-New York Long Island | Lake Success, New York, United States | Recruiting |
| Providence Cancer Institute | Portland, Oregon, United States | Recruiting |
| The University of Texas MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
| University of Texas Health Science Center at Houston | Houston, Texas, United States | Recruiting |
| START Mountain Region | West Valley City, Utah, United States | Recruiting |
| ICON Cancer Centre Wesley | Auchenflower, Queensland, Australia | Recruiting |
| ICON Cancer Centre Kurralta Park | Kurralta Park, South Australia, Australia | Recruiting |
| Austin Health- Olivia Newton John Cancer Center | Heidelberg, Victoria, Australia | Recruiting |
| Oxford University Hospitals NHS Foundation Trust | Oxford, United Kingdom | Recruiting |
| The Royal Marsden NHS Foundation Trust | Sutton, United Kingdom | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06242470